MA38393A3 - Composés hétéroaryle et utilisations associées - Google Patents

Composés hétéroaryle et utilisations associées

Info

Publication number
MA38393A3
MA38393A3 MA38393A MA38393A MA38393A3 MA 38393 A3 MA38393 A3 MA 38393A3 MA 38393 A MA38393 A MA 38393A MA 38393 A MA38393 A MA 38393A MA 38393 A3 MA38393 A3 MA 38393A3
Authority
MA
Morocco
Prior art keywords
protein kinase
heteroaryl compounds
related uses
compositions
carcinomas
Prior art date
Application number
MA38393A
Other languages
English (en)
Other versions
MA38393B1 (fr
Inventor
Laura Akullian D'agostino
Robert Tjin Tham Sjin
Deqiang Niu
Joseph John Mcdonald
Zhendong Zhu
Haibo Liu
Hormoz Mazdiyasni
Russell C Petter
Juswinder Singh
Matthieu Barrague
Alexandre Gross
Mark Munson
Darren Harvey
Andrew Scholte
Sachin Maniar
Original Assignee
Sanofi Sa
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Celgene Avilomics Research Inc filed Critical Sanofi Sa
Publication of MA38393A3 publication Critical patent/MA38393A3/fr
Publication of MA38393B1 publication Critical patent/MA38393B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des composés utiles comme inhibiteurs de protéines kinases, contenant un reste de cystéine dans le site de liaison atp. L'invention concerne également des compositions pharmaceutiquement acceptables comprenant des quantités thérapeutiquement efficaces d'un ou de plusieurs composés inhibiteurs de protéines kinases, ainsi que des méthodes d'utilisation de ces compositions dans le traitement de cancers et de carcinomes.
MA38393A 2014-03-13 2014-03-14 Composés hétéroaryle et utilisations associées MA38393B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305361 2014-03-13
PCT/US2014/029270 WO2014144737A1 (fr) 2013-03-15 2014-03-14 Composés hétéroaryle et utilisations associées

Publications (2)

Publication Number Publication Date
MA38393A3 true MA38393A3 (fr) 2018-05-31
MA38393B1 MA38393B1 (fr) 2018-11-30

Family

ID=50390019

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38393A MA38393B1 (fr) 2014-03-13 2014-03-14 Composés hétéroaryle et utilisations associées

Country Status (13)

Country Link
US (1) US9663524B2 (fr)
EP (1) EP2968337B1 (fr)
JP (1) JP6576325B2 (fr)
KR (1) KR102219695B1 (fr)
CN (2) CN105307657B (fr)
AU (1) AU2014228746B2 (fr)
BR (1) BR112015022191A8 (fr)
EA (1) EA036160B1 (fr)
MA (1) MA38393B1 (fr)
MX (1) MX2015011514A (fr)
PE (1) PE20151776A1 (fr)
SG (1) SG11201507478VA (fr)
WO (1) WO2014144737A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
RS62233B1 (sr) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitori receptora fibroblast faktora rasta
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
CN109776525B (zh) 2013-04-19 2022-01-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
SG11201602069WA (en) * 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
EP3060560A1 (fr) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibiteurs du récepteur du facteur de croissance des fibroblastes
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
EP3171874B1 (fr) 2014-07-21 2020-11-18 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'imidazolyl kinase et leurs utilisations
DK3172213T3 (da) 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
AU2015300782B2 (en) 2014-08-08 2020-04-16 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
WO2016054483A1 (fr) 2014-10-03 2016-04-07 Novartis Ag Utilisation de dérivés pyridyle bicycliques à anneaux fusionnés en tant qu'inhibiteurs de fgfr4
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016238436A1 (en) 2015-03-25 2017-08-17 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2016168331A1 (fr) 2015-04-14 2016-10-20 Eisai R&D Management Co., Ltd. Composé inhibiteur de fgfr4 cristallin et utilisations de celui-ci
JP7372740B2 (ja) 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
KR20180002053A (ko) * 2016-06-28 2018-01-05 한미약품 주식회사 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
WO2018055503A1 (fr) 2016-09-20 2018-03-29 Novartis Ag Combinaison comprenant un antagoniste de pd-1 et un inhibiteur de fgfr4
CN109922804B (zh) 2016-11-02 2023-11-17 诺华股份有限公司 Fgfr4抑制剂和胆汁酸螯合剂的组合
JP6919922B2 (ja) * 2016-12-19 2021-08-18 アビスコ セラピューティクス カンパニー リミテッド Ｆｇｆｒ４阻害剤、その製造方法と薬学的な応用
CN108503593B (zh) * 2017-02-28 2021-04-27 暨南大学 2-氨基嘧啶类化合物及其应用
BR112019017741A2 (pt) 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN110914267B (zh) * 2017-07-19 2022-07-12 江苏奥赛康药业有限公司 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用
CN109384790B (zh) * 2017-08-08 2022-05-10 药捷安康(南京)科技股份有限公司 成纤维细胞生长因子受体抑制剂及其用途
CN109745325B (zh) * 2017-11-08 2022-02-15 上海翰森生物医药科技有限公司 Fgfr4抑制剂、其制备方法和用途
CN110386921A (zh) * 2018-04-23 2019-10-29 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂化合物
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
WO2019223766A1 (fr) * 2018-05-25 2019-11-28 上海和誉生物医药科技有限公司 Inhibiteur de fgfr, son procédé de préparation et son utilisation pharmaceutique
CN110577524B (zh) * 2018-06-07 2022-01-28 北京大学深圳研究生院 一种激酶选择性抑制剂
CN111936493B (zh) * 2018-06-19 2023-05-26 上海和誉生物医药科技有限公司 一种高选择性FGFRi抑制剂及其制备方法和应用
CN112119064B (zh) 2018-09-14 2023-06-23 上海和誉生物医药科技有限公司 Fgfr抑制剂、其制备方法和应用
WO2020177067A1 (fr) 2019-03-05 2020-09-10 Bioardis Llc Dérivés aromatiques, procédés de préparation et utilisations médicales de ceux-ci
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
EP3936509B1 (fr) * 2019-03-08 2024-07-31 Shouyao Holdings (Beijing) Co., Ltd. Inhibiteur de fgfr4 kinase, son procédé de préparation et son utilisation
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
WO2021108803A1 (fr) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Composés de pyrimidine pyridinone fusionnés en tant qu'inhibiteurs de jak
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
KR102382613B1 (ko) * 2020-01-15 2022-04-06 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물
AU2021436754A1 (en) * 2021-03-26 2023-10-12 Apeloa Pharmaceutical Co., Ltd. Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof
CA3215903A1 (fr) 2021-04-12 2022-10-20 Incyte Corporation Polytherapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
EP4352059A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CN113527311B (zh) * 2021-08-23 2022-05-06 中南大学湘雅医院 Fgfr4抑制剂、组合物及其在药物制备中的用途
WO2023039828A1 (fr) * 2021-09-17 2023-03-23 Nutshell Biotech (Shanghai) Co., Ltd. Composés cycliques fusionnés utiles en tant qu'inhibiteurs de tyrosine kinases fgfr4
CN113912602B (zh) * 2021-10-14 2023-05-05 温州医科大学 一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
WO2024199388A1 (fr) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 Composé agissant comme inhibiteur de myt1

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
MX9702245A (es) * 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
DE19802377A1 (de) 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
DE69939168D1 (de) 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
JP3593035B2 (ja) 1998-10-23 2004-11-24 エフ．ホフマン−ラ ロシュ アーゲー 二環式窒素複素環化合物
BR0013952A (pt) 1999-09-15 2002-05-14 Warner Lambert Co Pteridinonas como inibidores de cinase
EP1226144B1 (fr) 1999-10-21 2006-12-27 F. Hoffmann-La Roche Ag Heterocycles d'azote bicyclique substitues par de l'alkylamino en tant qu'inhibiteurs de proteine kinase p38
HUP0203564A3 (en) 1999-10-21 2004-07-28 Hoffmann La Roche Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
AP1333A (en) * 2000-08-04 2004-11-28 Warner Lambert Co 2-(4-pyridyl) amino-6-dialkoxyphenyl-pyrido [2,3-d] pyrimidin-7-ones.
ES2243568T3 (es) 2000-08-31 2005-12-01 F. Hoffmann-La Roche Ag 7-oxo-piridopirimidinas.
KR100571339B1 (ko) 2000-08-31 2006-04-17 에프. 호프만-라 로슈 아게 세포증식 억제제로서의 7-옥소 피리도피리미딘
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
WO2002076985A1 (fr) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
AU2003250475A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) * 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
EP1572682A4 (fr) 2002-12-20 2008-01-23 Pharmacia Corp Composés de pyrazole acyclique
US20050009849A1 (en) * 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
CA2521124A1 (fr) 2003-04-10 2004-10-21 F. Hoffmann-La Roche Ag Composes pyrimido
MXPA05011103A (es) 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
JP2007500725A (ja) 2003-07-29 2007-01-18 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての化合物および組成物
EP1673343A4 (fr) 2003-10-08 2008-09-10 Irm Llc Composes et compositions convenant comme inhibiteurs de proteine-kinases
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
JP5520433B2 (ja) 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
WO2005105097A2 (fr) 2004-04-28 2005-11-10 Gpc Biotech Ag Derives de pyridopyrimidine
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN1984914A (zh) 2004-08-31 2007-06-20 霍夫曼-拉罗奇有限公司 7－氨基－3－苯基－二氢嘧啶并[4,5－d]嘧啶酮的酰胺衍生物、其制备和作为蛋白激酶抑制剂的应用
CA2577275A1 (fr) 2004-08-31 2006-03-09 Astrazeneca Ab Derives de quinazolinone et utilisation de ces derives en tant qu'inhibiteurs du b-raf
ES2320570T3 (es) 2004-08-31 2009-05-25 F. Hoffmann-La Roche Ag Derivados de amida de 3-fenil-dihidropirimido (4,5-d)-pirimidinonas, su preparacion y empleo como agentes farmaceuticos.
WO2006038112A1 (fr) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Utilisation d'inhibiteurs de kinases pour favoriser la neochondrogenese
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
US20100234400A1 (en) 2005-06-10 2010-09-16 Irm Llc Compounds that maintain pluripotency of embryonic stem cells
WO2006137421A1 (fr) 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent pour administration topique
EP1910542B1 (fr) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions et procedes de traitement de maladies a l'aide de proteines de fusion fgfr
EP1906967A4 (fr) 2005-07-26 2010-07-28 Vertex Pharma Inhibition de kinase d'abl
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007071752A2 (fr) 2005-12-21 2007-06-28 Novartis Ag Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf)
CN101356159A (zh) 2005-12-22 2009-01-28 惠氏公司 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途
EP2027123B1 (fr) * 2006-05-11 2011-02-23 Irm Llc Composes inhibiteurs de proteines kinases et compositions comprenant de tels composes
WO2007136465A2 (fr) 2006-05-15 2007-11-29 Irm Llc Compositions et procédés utilisés en tant qu'inhibiteurs des kinases réceptrices fgf
EP1914234A1 (fr) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
EP2084159A1 (fr) 2006-10-16 2009-08-05 GPC Biotech Inc. Pyridoý2,3-d¨pyrimidines et utilisation de celles-ci en tant qu'inhibiteurs de kinases
WO2008150260A1 (fr) 2007-06-06 2008-12-11 Gpc Biotech, Inc. Inhibiteurs de kinase
WO2008051820A2 (fr) 2006-10-20 2008-05-02 Swagelok Company Amorçage d'arc à courant continu avec entrée universelle
JP2010509265A (ja) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
ATE490243T1 (de) * 2006-12-27 2010-12-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
WO2008077555A2 (fr) * 2006-12-27 2008-07-03 Sanofi-Aventis Nouveaux dérivés d'isoquinoline et d'isoquinolinone substitués
KR20100024932A (ko) 2007-06-15 2010-03-08 반유 세이야꾸 가부시끼가이샤 비사이클로아닐린 유도체
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
US7989465B2 (en) * 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US8216783B2 (en) 2008-04-14 2012-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
EP2269993B1 (fr) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. Dérivé de 2-aminoquinazoline
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
US20100121052A1 (en) 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
CA2745959A1 (fr) 2008-12-12 2010-06-17 Msd K.K. Derives de dihydropyrimidopirymidine
EP2376493B1 (fr) 2008-12-12 2016-10-05 Msd K.K. Dérivé de dihydropyrimidopyrimidine
CA2748181C (fr) 2009-01-06 2019-07-16 Nathanael S. Gray Composes pyrimido-diazepinone d'echafaudage de kinase et procedes de traitement de troubles
WO2011034907A2 (fr) * 2009-09-16 2011-03-24 Avila Therapeutics, Inc. Conjugués et inhibiteurs de protéine kinase
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
JP2013514986A (ja) 2009-12-18 2013-05-02 ノバルティス アーゲー 血液癌の処置方法
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
JP2014511395A (ja) * 2011-03-09 2014-05-15 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
RU2013143358A (ru) 2011-04-07 2015-05-20 Дженентек, Инк. Анти-fgfr4 антитела и способы их применения
MX355728B (es) 2011-05-17 2018-04-27 Univ California Inhibidores de cinasas.
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
MX2014005292A (es) 2011-11-04 2014-09-11 Afraxis Holdings Inc Inhibidores de pak para el tratamiento de síndrome del x frágil.
RU2664055C2 (ru) 2012-06-07 2018-08-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Дигидронафтиридины и родственные соединения, подходящие в качестве ингибиторов киназ для лечения пролиферативных заболеваний
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
RS62233B1 (sr) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitori receptora fibroblast faktora rasta
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
EP3019491A4 (fr) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc Inhibiteurs de kinase pour le traitement d'une maladie
EP3628749A1 (fr) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Fusions de ntrk2
EP3027654B1 (fr) 2013-07-30 2019-09-25 Blueprint Medicines Corporation Fusions de pik3c2g
RU2706235C2 (ru) 2013-10-17 2019-11-15 Блюпринт Медсинс Корпорейшн Композиции, пригодные для лечения расстройств, связанных с kit
WO2015058129A1 (fr) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Composés à utiliser pour traiter des troubles associés à l'enzyme kit
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
EP3060560A1 (fr) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibiteurs du récepteur du facteur de croissance des fibroblastes
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor

Also Published As

Publication number Publication date
SG11201507478VA (en) 2015-10-29
MX2015011514A (es) 2016-08-11
BR112015022191A8 (pt) 2018-01-23
CN105307657A (zh) 2016-02-03
CN111793068A (zh) 2020-10-20
BR112015022191A2 (pt) 2017-10-10
PE20151776A1 (es) 2015-12-11
JP2016519673A (ja) 2016-07-07
AU2014228746A1 (en) 2015-09-10
EP2968337A4 (fr) 2016-10-19
WO2014144737A1 (fr) 2014-09-18
EP2968337B1 (fr) 2021-07-21
AU2014228746B2 (en) 2018-08-30
KR20150131237A (ko) 2015-11-24
MA38393B1 (fr) 2018-11-30
KR102219695B1 (ko) 2021-02-25
EP2968337A1 (fr) 2016-01-20
US20160046634A1 (en) 2016-02-18
JP6576325B2 (ja) 2019-09-18
EA036160B1 (ru) 2020-10-08
EA201591420A1 (ru) 2016-02-29
CN105307657B (zh) 2020-07-10
US9663524B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
MA38393B1 (fr) Composés hétéroaryle et utilisations associées
TN2015000417A1 (en) Heteroaryl compounds and uses thereof
AU2018236800B2 (en) DNA-PK inhibitors
EA202091709A1 (ru) Ингибиторы днк-пк
BR112022002698A2 (pt) Compostos de imidazolil pirimidinilamina como inibidores de cdk2
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
UA115983C2 (uk) Інгібітори днк-пк
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA202091708A1 (ru) Ингибиторы днк-пк
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
EA201100078A1 (ru) Производные пиримидина в качестве ингибиторов киназы
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EA201692227A1 (ru) Производные сложных аминоэфиров
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
WO2016004280A3 (fr) Inhibiteurs de tyrosine kinase de bruton
WO2020106751A8 (fr) Inhibiteurs de gli1 utilisés en tant qu'agents thérapeutiques
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена